New quarterly report expected Apr 22, 2026. Report will refresh after results.
E
Edwards Lifesciences Corporation
EW · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Structural Heart's Best Franchise Priced for a Flawless Second Act
The market is treating TMTT optionality as a free call option layered on top of a stable TAVR compounder — but the FCF compression and ROIC slide since 2022 reveal that the optionality is being funded by eroding the quality of the core business, and the NCD review creates a single regulatory event that could either validate or demolish the entire early-intervention thesis in one decision.
Flowly Score
Apr 16 Close
-6%$79.05
Fair Value
$74.00
54
Averageat $79.05
Business Strength7/10
SAPIEN's clinical evidence fortress and RESILIA tissue platform create genuine switching costs that compound with every case done — this is a real moat, not marketing. The post-spinoff concentration is a double-edged sword: it clarifies the quality of what remains but removes any buffer if TMTT stumbles or TAVR faces reimbursement headwinds.
Financial Resilience5/10
The balance sheet is clean — substantial net cash, minimal debt — and the Altman Z-score signals no solvency risk whatsoever. But the FCF generation that once made this business exceptional has compressed markedly, with CapEx running ahead of depreciation and operating cash conversion well below the business's own history, signaling a company still building rather than harvesting.
Growth & Trajectory7/10
TAVR's runway is longer than consensus assumes — the NCD review, guideline changes in Europe, and the early-intervention evidence shift from PARTNER trial series all point to a procedure volume curve that isn't flattening yet. TMTT growing north of forty percent from a base that finally crossed half a billion is real progress, not noise, even if the $2B by 2030 target requires exceptional execution.
Valuation5/10at $84.26
A multiple in the mid-forties prices in a recovery trajectory that is plausible but not proven, at a moment when FCF yield is negligible and the stock is trading above most reasonable fair value estimates. The optionality in TMTT is legitimately worth something, but not as much as the current premium implies — there is no margin of safety here.
Risk5/10
The moat is durable enough that competitive displacement from Medtronic or Abbott in TAVR is a slow-moving threat, not an imminent one. But the CMS NCD review is a binary regulatory event with an asymmetric risk profile — favorable outcomes are already baked into the bull case, while an adversarial determination would hit both the revenue model and the multiple simultaneously.
Edwards owns one of the most defensible franchises in medical devices — a decade of randomized clinical evidence, physician training networks built procedure by procedure, and a tissue platform with real durability advantages create the kind of institutional entrenchment that degrades only slowly under competitive pressure. The quality is not in question. What is in question is whether you are being asked to pay for tomorrow's TMTT optionality before today's FCF has recovered from funding its construction — and the current multiple, sitting well above the five-year average on compressed cash generation, suggests the answer is yes. The next five years are a race on two tracks simultaneously. First, TAVR's early-intervention expansion: guideline changes in Europe, a US NCD review that could broaden coverage to younger and lower-risk patients, and clinical evidence pushing physicians toward treating symptomatic patients sooner rather than watching. This is a legitimate runway extension that most models underweight. Second, TMTT's commercial ramp: EVOQUE in tricuspid replacement and PASCAL's expanded indications represent an addressable market that dwarfs aortic stenosis, but mitral and tricuspid anatomy is messier, the evidence cycles are longer, and Abbott's entrenched position in mitral repair means Edwards enters as a challenger rather than a pioneer for the first time in its structural heart history. The single most concentrated risk is the CMS NCD review of TAVR coverage, expected to conclude in late 2026. The bull case already assumes expanded indications — asymptomatic patients, lower-age thresholds, broader risk categories — folded into investor expectations. If CMS moves in the opposite direction, tightening indications in a cost-containment moment, it doesn't just hit near-term procedure volumes — it collapses the early-intervention thesis that justifies the premium multiple, leaving a business trading at mid-forties earnings with a growth story that just lost its primary catalyst. That is a scenario the current price offers precisely zero cushion for.